Td Asset Management Inc Verve Therapeutics, Inc. Transaction History

Td Asset Management Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 08, 2024	BUY	$10.81 - $17.96 $138,368 - $229,888	12,800 Added 27.2%	59,856 $794,000
Q4 2023 Feb 12, 2024	BUY	$8.84 - $18.7 $141,386 - $299,087	15,994 Added 51.49%	47,056 $655,000
Q1 2023 May 10, 2023	BUY	$14.3 - $24.01 $88,660 - $148,862	6,200 Added 24.94%	31,062 $447,000
Q4 2022 Feb 06, 2023	BUY	$17.85 - $40.7 $202,062 - $460,724	11,320 Added 83.59%	24,862 $481,000
Q3 2022 Nov 07, 2022	BUY	$15.63 - $41.49 $211,661 - $561,857	13,542 New	13,542 $463,000

186

73.3M

85K

215K

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $291M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Td Asset Management Inc with notifications on news.